Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,205
datasets available to search
ShareScore release 0.9.0
Dataset results
1,205 results for “vaccine responses”
Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
ClinicalTrials.gov study NCT00335881. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults
ClinicalTrials.gov study NCT00094705. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
ClinicalTrials.gov study NCT00516035. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Influenza Vaccine Elicited Immune Response in Immunocompromised Patients
ClinicalTrials.gov study NCT06738082. IPD Sharing: NO. Countries: 1. Publications: 18.
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
ClinicalTrials.gov study NCT01084291. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
ClinicalTrials.gov study NCT00428337. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
ClinicalTrials.gov study NCT00192322. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
ClinicalTrials.gov study NCT04596098. IPD Sharing: UNDECIDED. Countries: 1. Publications: 17.
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
Open the record for dataset details and reuse information.
Data from: A field study evaluating the humoral immune response in Mongolian sheep vaccinated against sheeppox virus
Open the record for dataset details and reuse information.
Supporting transcriptomic data for: "Human transcriptomic response to the VSV-vectored Ebola vaccine"
<p>This is the complete dataset of transcriptomic data obtained from whole blood RNA of volunteers vaccinated with a high dose of the rVSV-ZEBOV vaccine against Ebola virus disease in the Geneva clinical trial.</p> <p>The Counts_Table.csv file contains gene expression data (counts) for genes in the Ion Ampliseq human Gene expression kit panel. </p> <p>The Descriptive_Table.csv contains descriptive data of the subjects for differential expression analysis.</p>
Data from: Vaccination method affects immune response and bacterial growth but not protection in the Salmonella Typhimurium animal model of typhoid
Understanding immune responses elicited by vaccines, together with immune responses required for protection, is fundamental to designing effective vaccines and immunisation programs. This study examines the effects of the route of administration of a live attenuated vaccine on its interactions with, and stimulation of, the murine immune system as well as its ability to increase survival and provide protection from colonisation by a virulent challenge strain. We assess the effect of administration method using the murine model for typhoid, where animals are infected with S. Typhimurium. Mice were vaccinated either intravenously or orally with the same live attenuated S. Typhimurium strain and data were collected on vaccine strain growth, shedding and stimulation of antibodies and cytokines. Following vaccination, mice were challenged with a virulent strain of S. Typhimurium and the protection conferred by the different vaccination routes was measured in terms of challenge suppression and animal survival. The main difference in immune stimulation found in this study was the development of a secretory IgA response in orally-vaccinated mice, which was absent in IV vaccinated mice. While both strains showed similar protection in terms of challenge suppression in systemic organs (spleen and liver) as well as survival, they differed in terms of challenge suppression of virulent pathogens in gut-associated organs. This difference in gut colonisation presents important questions around the ability of vaccines to prevent shedding and transmission. These findings demonstrate that while protection conferred by two vaccines can appear to be the same, the mechanisms controlling the protection can differ and have important implications for infection dynamics within a population.
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Introduction: Prompted by recent amendments of Yellow Fever (YF) vaccination guidelines from boost to single vaccination strategy and the paucity of clinical data to support this adjustment, we used the profile of the YF-specific CD8+ T-cell subset profiles after primary vaccination and neutralizing antibodies as a proxy for potentially longer lasting immunity. Methods and Findings: PBMCs and serum were collected in six individuals on days 0, 3, 5, 12, 28 and 180, and in 99 individuals >10 years after YF-vaccination. Phenotypic characteristics of YF- tetramer+ CD8+ T-cells were determined using class I tetramers. Antibody responses were measured using a standardized plaque reduction neutralization test (PRNT). Also, characteristics of YF-tetramer positive CD8+ T-cells were compared between individuals who had received a primary- and a booster vaccination. YF-tetramer+ CD8+ T-cells were detectable on day 12 (median tetramer+ cells as percentage of CD8+ T-cells 0.2%, range 0.07–3.1%). On day 180, these cells were still present (median 0.06%, range 0.02–0.78%). The phenotype of YF-tetramer positive CD8+ T-cells shifted from acute phase effector cells on day 12, to late differentiated or effector memory phenotype (CD45RA-/+CD27-) on day 28. Two subsets of YF-tetramer positive T-cells (CD45RA+CD27- and CD45RA+CD27+) persisted until day 180. Within all phenotypic subsets, the T-bet: Eomes ratio tended to be high on day 28 after vaccination and shifted towards predominant Eomes expression on day 180 (median 6.0 (day 28) vs. 2.2 (day 180) p = 0.0625), suggestive of imprinting compatible with long-lived memory properties. YF-tetramer positive CD8+ T-cells were detectable up to 18 years post vaccination, YF-specific antibodies were detectable up to 40 years after single vaccination. Booster vaccination did not increase titers of YF-specific antibodies (mean 12.5 vs. 13.1, p = 0.583), nor induce frequencies or alter phenotypes of YF-tetramer+ CD8+ T-cells. Conclusion: The presence of a functionally competent YF-specific memory T-cell pool 18 years and sufficient titers of neutralizing antibodies 35–40 years after first vaccination suggest that single vaccination may be sufficient to provide long-term immunity.
Influenza vaccination stimulates maturation of the human T follicular helper cell response
<p><strong>Data</strong></p> <p>The two rds-format (R Data Serialization) files contain Seurat objects used for analyses.</p> <p>intergrated_Tcells_harmony_bydonor.rds contains all T cells.</p> <p>intergrated_Tfh_harmony_bydonor.rds is a subset of the previous file containing the TFH and Treg lineages.</p> <p>Set2_10x_clones.tsv is paired TCR information for cells from the 10X experiment for all cells in intergrated_Tcells_harmony_bydonor.</p> <p>TwoYear_LN_Bcell_freq_time.csv contains the B cell subset frequencies in the lymph node by time point.</p> <p>Ali_paired_sc_clones_JCC283.tsv contains paired TCR sequences of cTFH and LN TFH cells obtained by single-cell sorting and target PCR. </p> <p>Ali_bulk_allDonor_clones.tsv contains bulk TCR alpha and beta chains of sorted cTFH and LN TFH generated using a 5'-RACE protocol.</p> <p><strong>The code that accompanies these data is available on GitHub (https://github.com/sschattgen/Flu_TFH_paper)</strong></p> <div> <div> <div> <p><strong>Reads for samples from year 2 for 321-05, year 1 and year 2 312-04, all samples from 321-07, and all samples from 321-08 are available on the NCBI Sequence Read Archive (SRA) under BioProject accession PRJNA1132302. Reads for year 1 samples for 321-05 are available on SRA under BioProject PRJNA610059.</strong></p> </div> </div> </div>
Additional ELISA data for the manuscript "Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice"
<p>This repository contains the source ELISA data for supplementory figure 4 of the manuscript "Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice" currently under review by PLOS ONE.</p> <p>Files include Raw OD's per plate and reported values.</p> <p>Purpose:<br> These ELISA's were performed to assess differences in hemagglutinin (HA) specific IgG responses in sera of mice immunized with one of three univeral flu vaccine regimens conferring different levels of protection against lethal H1N1 influenza challenge.</p> <p>Method:<br> Naïve 8-weeks old mice were immunized three times, at days 0, 21 and 42 with different immunogens. One cohort of animals was vaccinated received a largely protective vaccine containing a high dose (30 µg) of a trimeric full-length H1 HA antigen (FL H1#2316) that provides heterologous protection against H1N1 A/Netherlands/602/2009 while a second cohort received a minimally protective vaccine containing a high dose (30 µg) of an HA stem-based monomeric antigen (UFV#4157) derived from FL H1#2316. To control for differences in immune responses related to the dose rather than intrinsically protective properties of the used immunization antigen, a lower but partiallly protective protective dose (0.3 µg) of FL H1#2316 was used for immunizations of a third cohort, while as a negative control for survival a fourth cohort was immunized with PBS only. All the immunized proteins are based on the HA of H1N1 A/Brisbane/59/07. All immunizations, including mock-immunizations with PBS, were adjuvanted with alum. 8 animals per cohort were sacrificed at 8 different timepoints (days 4, 7, 12, 19, 25, 28, 46 and 49) to obtain serum and lymphnodes for analaysis To assess the protective efficacy of the administered vaccine regimens, 10 animals per immunized cohort were challenged intranasally with a lethal dose of 25xLD50 H1N1 A/Netherlands/602/2009. 2 days prior to the challenge, on day 68, we also took a blood sample to check the pre-challenge titers of each animal.</p> <p>On the serum isolated on day 4, 7, 12, 19, 25, 28, 46 49 andd 68, we performed two ELISA experiments. In one ELISA we coated the plates with the recombinant HA of A/Brisbane/59/07, homologous to the used vaccine candidates, and in the other ELISA we used recombinant HA of A/California/07/09, 99.4% homologous to the challenge strain H1N1 A/Netherlands/602/2009.</p> <p>Results:<br> At the end of the three immunizations we see that the IgG titers against A/Brisbane/59/07 reach similar levels in both the 30µg and 0.3µg UFV#2316 cohorts, whearas the responses of the headless UFV#4157 are slightly lower. Because the titers against the rHA A/California/07/09 in the UFV#4157 cohort is similar to both UFV#2316 regimen we can allocate the differences observed in the A/Brisbane/59/07 ELISA to the absense or availablility of the immunodominant head domain. In conclusion we do not see any differences in antibody titers that can correlate with the challenge outcome at the end of the study:<br> 30µg UFV#2316 80% protection<br> 0.3µg UFV#2316 60% protection<br> 30µg UFV#4157: 0% protection<br> PBS: 0% protection</p>
Differences in SARS-CoV-2 specific humoral and cellular immune responses after contralateral and ipsilateral COVID-19 vaccination
<p>In an observational study, 303 previously naive individuals were recruited, who received the second dose of the COVID-19 vaccine BNT162b2 on either the ipsilateral (n=147) or the contralateral side (n=156). Spike-specific IgG, IgG-avidity, and neutralizing antibodies were quantified using ELISA and a surrogate assay 2 weeks after dose 2. A subgroup of 143 individuals (64 ipsilateral, 79 contralateral) was analysed for spike-specific CD4 and CD8 T-cells using flow-cytometry.</p>
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
ClinicalTrials.gov study NCT00693706. IPD Sharing: YES. Countries: 1. Publications: 0.
The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines
ClinicalTrials.gov study NCT00792610. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
ClinicalTrials.gov study NCT01644149. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
ClinicalTrials.gov study NCT01831934. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.